GLP-1s: A win-win for society and life insurers alike
Fidelity's Fahim Razzaque believes that when innovation creates a game-changing ripple effect across multiple industries, as may be the case with GLP-1 drugs, investors should pay attention.
- Groundbreaking advances in weight-loss treatments have been lauded for helping people live a longer, healthier life, according to Fidelity Portfolio Manager Fahim Razzaque, who notes that they also could result in life insurers becoming stronger and more profitable.
- "Life insurance is essentially a bet on time, requiring insurers to calculate premiums based on how long they expect policyholders to live," says Razzaque, who manages Fidelity® Select Insurance Portfolio. "Enter GLP-1s, potential game-changers in extending life expectancy and improving quality of life that, for insurers, could lead to fewer payouts and more time to grow their reserves."
- In running the industry-based, equity-focused strategy since 2022, Razzaque relies on bottom-up, fundamental research, supported by Fidelity's global financials team, to seek insurance firms generating high and sustainable returns on equity, given these businesses' unique underwriting, distribution and scale advantages. He prefers companies with strong organic reinvestment opportunities that may help drive faster earnings growth.
- "With GLP-1 drugs, we can now see where the science of longevity meets the business of risk," says Razzaque. "Simply put, these breakthrough treatments reduce the odds of a customer dying while a life insurance policy is still active."
- He explains that this lowers the likelihood of large payouts to policyholders, which may help significantly boost profit margins for life insurance firms.
- "But the potential boost to insurers doesn't stop there," Razzaque notes. "Over time, as insurers gain confidence in an improved mortality rate, they will be able to pass the savings along to customers, quite possibly resulting in lower premiums and better pricing becoming the new norm."
- Razzaque believes several of the fund's holdings are well-positioned to potentially benefit from the emergence of GLP-1 drugs and other health care advances, especially Reinsurance Group of America, a sizable position on April 30.
- "As a reinsurer, RGA provides coverage to insurance companies, making it uniquely positioned to ride improving trends in life expectancy," Razzaque notes. "In other words, when its policyholders live longer and age with reduced health complications, RGA should find itself with fewer and/or less-expensive claims to pay."
- That said, he also offers a dash of caution, conceding that it is still early days in terms of assessing the financial implications of GLP-1 drugs on both life insurers and reinsurers.
- Despite his optimism, he contends that more data is needed before life insurers start to reduce premiums or reserves, although the trajectory could be quite promising.
- "In the end, this is more than just a story about drugs or insurance," Razzaque concludes. "I have had multiple discussions with industry professionals who are equally enthusiastic about what the future may hold: opportunities for better health, more-durable insurance businesses and the potential for outsized investment returns."
Fidelity Select Insurance Portfolio (FSPCX)
Seeks capital appreciation.
Related insights
View all


For specific fund information such as standard performance and holdings, please go to the "Funds Managed" link on this page.
Investment decisions should be based on an individual’s own goals, time horizon, and tolerance for risk. Nothing in this content should be considered to be legal or tax advice, and you are encouraged to consult your own lawyer, accountant, or other advisor before making any financial decision. These materials are provided for informational purposes only and should not be used or construed as a recommendation of any security, sector, or investment strategy.
Fidelity does not provide legal or tax advice and the information provided herein is general in nature and should not be considered legal or tax advice. Consult with an attorney or a tax professional regarding your specific legal or tax situation.
Past performance and dividend rates are historical and do not guarantee future results.
Investing involves risk, including risk of loss.
Diversification does not ensure a profit or guarantee against loss.
Sector funds can be more volatile because of their narrow concentration in a specific industry. Growth stocks can perform differently from other types of stocks and the market as a whole and can be more volatile than other types of stocks. Value stocks can perform differently than other types of stocks and can continue to be undervalued by the market for long periods of time. • Stock markets, especially foreign markets, are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. • Foreign securities are subject to interest rate, currency exchange rate, economic, and political risks, all of which are magnified in emerging markets. • In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation, credit, and default risks for both issuers and counterparties. • Lower-quality bonds can be more volatile and have greater risk of default than higher-quality bonds. • The municipal market is volatile and can be significantly affected by adverse tax, legislative, or political changes, and the financial condition of the issuers of municipal securities. • The securities of smaller, less well-known companies can be more volatile than those of larger companies. • The funds can invest in securities that may have a leveraging effect (such as derivatives and forward-settling securities) that may increase market exposure, magnify investment risks, and cause losses to be realized more quickly. • Leverage can magnify the impact of adverse issuer, political, regulatory, market, or economic developments on a company. In the event of bankruptcy, a company’s creditors take precedence over the company’s stockholders. Although the companies that the fund invests in may be highly leveraged, the fund itself does not use leverage as an investment strategy. Changes in real estate values or economic downturns can have a significant negative effect on issuers in the real estate industry. In the event of bankruptcy, a company’s creditors take precedence over the company’s stockholders. Third-party marks are the property of their respective owners; all other marks are the property of FMR LLC.